SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-327159
Filing Date
2021-11-12
Accepted
2021-11-12 06:16:08
Documents
17
Period of Report
2021-11-09
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d211688d8k.htm   iXBRL 8-K 29676
2 EX-1.1 d211688dex11.htm EX-1.1 238633
3 EX-5.1 d211688dex51.htm EX-5.1 8108
4 EX-99.1 d211688dex991.htm EX-99.1 8277
5 EX-99.2 d211688dex992.htm EX-99.2 9348
9 GRAPHIC g211688dsp50.jpg GRAPHIC 3441
  Complete submission text file 0001193125-21-327159.txt   492142

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20211109.xsd EX-101.SCH 2874
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20211109_lab.xml EX-101.LAB 17374
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20211109_pre.xml EX-101.PRE 10941
10 EXTRACTED XBRL INSTANCE DOCUMENT d211688d8k_htm.xml XML 3205
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 211399092
SIC: 2834 Pharmaceutical Preparations